Summary The incidence of subsequent primary cancers was assessed in relation to treatment for a cohort of 7,203 patients from the Birmingham and West Midlands Cancer Registry diagnosed between 1957 and 1976. The total of 213 cancers observed one or more years after treatment for ovarian cancer (mean follow-up=6.5 person-years) represented a significant excess (observed (0)=213, expected (E)= 140.07, relative risk (RR) = 1.5, 95% CI 1.3-1.7, P.<0.001). Among patients whose treatment included chemotherapy (CT), with or without radiotherapy (RT), the risk of acute and non-lymphocytic leukaemia (A+NLL) was significantly increased (O= 5, E=0.18, RR=27.8, 95% CI 9.0-64.8, P<0.001). The relative risks of A+NLL following RT without CT (RR=4.5) and after other treatments (RR=2.9) were not significantly in excess of 1.0. Significant excesses of subsequent cancers were observed at several sites: breast (RR= 1.7, 95% CI 1.3-2.2), lung (RR=2.0, 95% CI 1.3-3.4), colon and rectum (RR= 1.6, 95% CI 1.1-2.3), urinary system (RR= 1.9, 95% CI 0.9-3.7), nervous system (RR=3.3, 95% CI 1.2-7.3) and connective tissue (RR=6.7, 95% CI 1.8-17.1) but the relationship with type of treatment was not so clearly defined as that for leukaemia. Although the treatment groups were broad and based on routinely collected data, they can enhance the use of cohort analyses for exploratory and monitoring purposes.
The overall survival of patients with ovarian cancer is very poor, because many present with late-stage disease. However, those treated radically for less extensive disease may survive for long periods and be at risk of subsequent primary cancer. Among other factors, the type of treatment used might affect this subsequent risk: removal of the ovaries, especially in younger women, might reduce the later risk of breast cancer; pelvic irradiation might increase the risk of leukaemia and of some solid tumours, such as those found for cervical cancer patients (Day & Boice, 1983) ; intensive chemotherapy has also been linked with an increased risk of leukaemia in many clinical studies. Cytotoxic alkylating agents are potential leukaemogens but whether they will prove to be generally carcinogenic for sites of solid cancers has still to be resolved.
Surgical treatment for ovarian cancer involves the removal of at least one ovary. Frequently both ovaries and the uterus are resected, thus removing these organs from further risk and also modifying hormonal influences. External pelvic irradiation has been used in the past to treat ovarian cancer. Chemotherapy, usually by single agent drug, came into more frequent use in the mid-1960s with melphalan, thiotepa, chlorambucil and cyclophosphamide being the drugs most commonly used in the earlier years. Leukaemia following ovarian cancer was linked to chemotherapy (Reimer et al., 1978) and a review of five clinical trials also showed a high relative risk of acute and non-lymphocytic leukaemia in patients treated by alkylating agents but not radiotherapy (Greene et al., 1982) . A cohort analysis of ovarian cancer patients based on international registry data demonstrated an increased risk of leukaemia and of certain other sites of solid tumours which, in the absence of specific therapy data, were suggestive of possible treatment effects (Kaldor et al., 1987) .
Although cytotoxic drugs and radiation may act as primary carcinogens both may have an indirect effect of increasing cancer risk by immunodepression. Immunodepressant therapy has been linked with the development of nonHodgkin's lymphoma and skin cancer (Kinlen et al., 1979) .
The present study was undertaken (i) to assess the incidence of subsequent primary cancers in a series of patients with ovarian cancer drawn from the population-based data of the Birmingham and West Midlands Cancer Registry, and (ii) to ascertain whether any increased risks could be attributable to treatment in this context. The overall results from this series were included in a collaborative registry study Received 23 August 1988 , and in revised form, 17 November 1988. (Kaldor et al., 1987) but the data have been re-analysed by treatment group for this present report.
Materials and methods

Study population
The series included all patient registered with cancer of the ovary or fallopian tube (International Classification of Diseases, 8th Revision (ICD8) -rubric 183) between 1957 and 1976. A total of 7,203 patients were followed to death or to 31 December 1982, among whom 61 cases were lost to active follow-up (0.8%), 11 having left the country.
Treatment
Four categories of treatment were considered: (1) RT, radiotherapy only; (2) CT, chemotherapy only; (3) RT+CT, radiotherapy and chemotherapy, either concurrent or at intervals; (4) OT, other, i.e. not treated, surgery only, surgery and hormone, hormone only. Patients in groups 1-3 may also have been treated surgically with or without hormones. Where appropriate, groups 1 and 3 have been combined as 'any RT' and groups 2 and 3 as 'any CT'.
Statistical methods
Subsequent cancers were identified from routine flagging of registry data, scrutiny of case-notes at active follow-up and from the multiple primary index. Equivocal cases were routinely reviewed by a consultant to the Registry for a final decision. Information held in the Registry on such cases was reviewed to ensure their eligibility for the study.
All cancers observed either coincidentially or within the first year of follow-up were excluded from the analysis together with the expected numbers for the first year to avoid possible bias in the ascertainment of early subsequent (Rothman & Boice, 1979) . Differences between RRs were tested by x2 analyses.
Excess morbidity rates (EMR) were computed as: (observed-expected number)/person years at risk (PYR) x 103. Treatment groups were compared and life-table estimates of risk were obtained by log-rank procedures (Peto et al., 1977 (Table IV) . When the results for any RT or CT were combined, the relative risk of subsequent breast cancer was 1.6 and was not significantly different from the risk in the OT group (Table VI) . However, In the combined RT/CT groups the risk of connective tissue cancers was increased 1-9 years after the ovarian cancer (Table VII) and an excess of marginal significance was also found for cancers of the nervous system in patients receiving any RT in these earlier years of follow-up but a moderate increase in all patients and in both time-periods was observed. The relative risk of lung cancer for 10+ years of follow-up was significantly higher than for 1-9 years (x= 4.8, P<0.05) but, again, the increase was not specifically related to the radiotherapy (Table VII) . The risk of colo-rectal cancers was significantly increased in the OT group 1-9 years after treatment of the ovarian cancer, and the relative risk was significantly higher in this group than in the combined RT/CT groups. No excess was found at 10+ years.
Pelvic irradiation will deliver a relatively high dose to the small intestine, colon, rectum, bladder, bone (-2,000-6,000 rad), kidney and connective tissue (-200-700 rad). The combined result for these sites in the RT group showed no additional risk 10 or more years after treatment: 1-9 years 0=7, E=4.9, RR=1.4; 10+ years 0=4, E=3.3, RR= 1.2.
Although genital sites within the pelvic beam might also be at high risk, surgical removal of the uterus and/or ovaries has not been allowed for in the expected numbers. The Such relationships were demonstrated in the early multiple primary studies (Schottenfeld & Berg, 1971; Schoenberg & Christine, 1974 , Prior & Waterhouse, 1981b involving mainly breast, corpus uteri and colon and were tentatively attributed to common hormonal factors. patients. Increased risks associated with radiotherapy were found for endometrium and bladder (Reimer et al., 1978) and for colon (Curtis et al., 1985) . In patients treated between 1970 and 1975 (Reimer et al., 1978) a nine-fold risk of leukaemia was found in association with chemotherapy, but not radiotherapy, but in the Connecticut Registry material, which included registrations up to 1982, the risk of acute non-lymphatic leukaemia was significantly increased in both the irradiated and non-irradiated groups, although chemotherapy may have been used in both (Curtis et al., 1985) . The overall relative risk of subsequent primaries in our series of 1.5 was marginally higher than the 1.2 of the recent international study (Kaldor et al., 1987) (Day & Boice, 1983) who had also received pelvic irradiation, particularly external irradiation (Boice et al., 1987) . No excess of leukaemia was found in the Birmingham series of cervical cancer patients, which formed part of the International Study, because, possibly, a higher proportion were treated solely by intracavitary radium, external irradiation being reserved for patients with disseminated disease (Prior & Brown, 1983) . The lack of effect in the RT + CT group might weigh against a treatment effect for the individual modalities. However, only a small group (609 patients) received both treatments of whom only 16.3% survived 5 years. It seems likely, therefore, that in this group the treatments were given, either together or at an interval, to palliate progressive disease and that doses would have been relatively lower and of shorter duration.
In a recent review of 83 reported cases of A + NLL following ovarian cancer (De Gramont et al., 1986) , all but two patients had received at least one alkylating drug; melphalan (40%), cyclophosphamide (18%), thiotepa (16%), chlorambucil (16%), 5-fluorouracil (16%) and treosulphan (14.5%), the mean duration of chemotherapy being 31.4 months (range 2-90 months) and the mean interval between cancers being 57.3 months (range 15 143 months). The five patients in our series who developed A+NLL had received cyclophosphamide, trenimon and thiotepa. The average duration of therapy (48 months) and the mean interval between ovarian cancer and A + NLL (60 months) were consistent with the above report. Our results are also consistent with the general finding in the collaborative registry study (Kaldor et al., 1987) where the overall risk of A+NLL was 3.4 (after exclusion of our results) compared with 7.0 (95% CI 3.2-13.2) in our series and the risk was found to remain high beyond 10 years of follow-up. Both the EMR of 2.4 per 103 PYR and the cumulative risk of 3.1% of A+NLL in our series of ovarian cancer patients were marginally higher than those found for Hodgkin's disease treated by chemotherapy, 1.0 per 103 PYR and 1.7% respectively (Prior & Pope, 1988) . This difference may arise because, although treatment for Hodgkin's disease is aggressive, the cyclical nature of the dosage may allow some bone marrow recovery whereas, in general, chemotherapy for ovarian cancer was continuous and of long duration. The two cases of the A + NLL found in the OT group, although not constituting a significant excess, gave a RR of 2.5. However, it was found that the patient developing A+NLL within 2 years of the ovarian cancer had previously been treated by splenectomy for aplastic anaemia and may, therefore, have been predisposed to leukaemia (Van Leeuwen et al., 1987) . The second case developed acute monocytic leukaemia some 22 years after the ovarian cancer when the expected number was approximately 1.0, and may, therefore, represent a chance effect. Breast Pelvic irradiation might expose the breast to a small dose of around 30 rad (Stovall, 1983) and be a potential source of increased risk, whereas ablation of the ovaries might decrease the risk. In a similar study of cervical cancer such a reduction was shown mainly for women irradiated before the age of 40 years, although the risk was reduced across all agegroups (Day & Boice, 1983) . In a case-control study of this same material, however, no dose relationship could be demonstrated for breast (Boice et al., 1987) . Although a general consensus supports a hormonal relationship between cancers of the breast and ovary, the mechanism is not clear. The fact that the majority of patients in our series did not have a functioning ovary suggests that the increased risk of breast cancer was not directly due to the action of ovarian hormones but to other common aetiological factors. The overall relative risk in our series (1.7, 95% CI 1.3-2.2) was marginally higher than that of 1.4 found in the international study (Kaldor et al., 1987) . This difference is probably due to the inclusion of third and later primaries in the analysis.
Urinary system An increased risk of bladder cancer has been reported after pelvic irradiation for benign disease (Wagoner, 1984) and for cancer of the cervix (Day & Boice, 1983) . Data from the atomic bomb survivors (Preston, 1987) and from cervical cancer patients surviving 10 or more years (Boice et al., 1987) are suggestive of a radiation dose response for bladder cancer. There is also evidence that alkylating agents, in particular cyclophosphamide, are associated with bladder cancer (Kinlen, 1981; IARC, 1981) . Cyclophosphamide was a commonly used drug in our series but an RT/CT effect was not supported by our data, the excess being mainly in the OT group. There were, however, relatively few long-term survivors in the RT/CT group.
Connective tissue
Although the excess of soft tissue sarcomas occurred mainly in the RT/CT groups 1-9 years after first treatment, the results were not conclusive. The one case in the OT group at 10+ years had in fact been treated for breast cancer 27 years previously but radiotherapy for this condition could not be confirmed. Similar excesses of connective tissue cancers were found in the collaborative registry studies of cervical cancer (Day & Boice, 1983) and of ovarian and testicular cancer (Kaldor et al., 1987) but, again, no clear distinction with type of treatment could be made.
Nervous system
Radiation doses to the brain from pelvic irradiation are likely to be low, probably less than 10 rads (Stovall, 1983) . A marginal exccess of cancers was found in the RT group (0=4, E=0.8, RR=5.0, P<0.01) the excess risk, again, occurring mainly in the first nine years of follow-up, but with a generalised elevation of risk. Five of the cancers observed occurred in various lobes of the brain and were of varying histological type including one meningioma; the sixth cancer was a meningioma of the spinal cord. In the collaborative registry study a small excess of nervous system tumours was found in the ovarian cohort (Kaldor et al., 1987) but a small deficit occurred in the cohort of cervical cancer patients (Day & Boice, 1983) . Deaths from cancers of the central nervous system were, however, increased in patients receiving one course of radiotherapy for ankylosing spondylitis (Darby et al., 1987) .
Respiratory system
Although lung contributes to the excess in the RT group and is in excess 10 or more years after treatment, an effect for RT is not strongly supported. Only moderate excesses of lung cancer were found in the collaborative registry study (Kaldor et al., 1987) and in an individual contribution to this study (Coleman et al., 1987) . Although radiation has been implicated in the development of lung cancer (Smith & Doll, 1982; Kato & Schull, 1982) , no definitive effect for RT was found after pelvic irradiation for cervical cancer (Day & Boice, 1983 ) from which the lung might receive a typical dose of around 30rads (Stovall, 1983) . Two further studies reported increased risks of lung cancer after ovarian cancer but, again, no radiation effect could be demonstrated (Reimer et al., 1978; Curtis et al., 1985) . However, our results for lung and urinary system could be consistent with a smoking or environmental pollution effect in the series (Mattison & Thorgeirsson, 1978; Wellington et al., 1979) , with the lower risk in the early years of follow-up reflecting our policy of cautious registration of lung tumours occurring soon after a first primary.
Colon and rectum A relationship between cancers of the ovary and colon has been reported from many studies of multiple primary cancers (Schoenberg et al., 1974; Storm & Ewertz, 1985; Curtis et al., 1985; Lynge et al., 1985; Hoar et al., 1985) . The association is apparent whichever cancer is taken as the index site. A similar relationship, but to a lesser extent, was found for ovary and rectum. The association has been variously attributed to 'hormonal' factors, low parity and diet. In the context of treatment effects it may be difficult to identify a moderate increase in risk due to radiotherapy against the general effect of a more than two-fold risk for these sites. Our results were, again, consistent with those of the international study.
Effects of methodology and other factors In general, our results support those of other series showing an association between cancers of the ovary, breast, corpus uteri and large bowel which can probably be attributed to common aetiological factors. Discrepancies in the levels of risks found in the different series may arise, in part, from differing approaches to the analysis. For example, in a previous paper on the association between ovary and breast (Prior & Waterhouse, 1981a) , we used a method of complementary analysis (Prior & Waterhouse, 1981b) to explore the joint association, when it was possible to include all coincidental and subsequent diagnoses. In the collaborative registry study (Kaldor et al., 1987) , all coincidental and first year cancers were excluded from the observed numbers and, in addition, all patients with previous or coincidental cancers were excluded from the cohort. The effect of applying the same rules to our analysis would have been to eliminate 26 cases from the observed numbers, 15 of whom had been treated by RT. Although this approach may not invalidate the analysis in the context of treatment effects, it may bias the estimates for aetiological associations unrelated to treatment: in our series a large proportion of previous and coincidental cancers and 12 of the 26 third or later primaries were of the breast, colon, rectum and uterus, which have been shown in many analyses to be associated with ovary. Thus an arbitrary exclusion of 4% of the original cohort, which may represent a high risk sub-group, will lead to an under-estimation of risk in later years.
The collaborative study used only the first subsequent cancer in the analysis. In our study we excluded no case from the cohort on the basis of coincidental cancers but we did exclude observed and expected numbers for the first year of follow-up from the analyses. The major difference in our approach was to retain patients, who developed a second primary, in the person-years at risk. The argument against this procedure was that treatment to the second primary might invalidate any conclusions drawn with respect to the initial treatment groups. Our contention was that, with respect to solid tumours, treatment effects in particular from radiotherapy would become apparent in long-term survivors and that third and subsequent primaries may well be of more relevance in this context. If the effects from superficial irradiation to rodent ulcers can be discounted, the inclusion of third and subsequent primaries did not alter the allocation of observed cases to our originally defined treatment groups.
Other factors might, however, affect the accuracy of the treatment groupings. It was found that if treatment to a primary, previous to or coincidental with the ovarian cancer, was taken into account, only 20 patients would need to be re-classified and the effect, if discernible, would enhance the risks in the OT and CT groups. Only one observed case was in doubt: a patient with a third primary of connective tissue mentioned above.
Incomplete reporting of treatments could also affect the allocation to treatment groups but it is not possible to validate the data for this without referring back to hospital records. Transcription errors of the data might also occur, but on the basis of a 4% sample we concluded that these would not have an appreciable effect on the expected numbers.
Despite some of the uncertainties inherent in routinely collected Registry data, our analyses have been able to demonstrate an increased risk of A +NLL in patients receiving chemotherapy. Whether we have seriously underestimated the risk from radiotherapy can only be resolved by further follow-up or more detailed case-control studies.
However, the results do suggest that analyses by treatment group, even in the broad categories used here, enhance the use of Registry data in exploratory cohort studies.
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